Harvard Apparatus Regenerative Technology, Inc. has rebranded itself as Biostage, Inc. to reflect a shift in its focus to bioengineered organ implants.
The Holliston company decided to make the change because of the evolution of a focus from commercializing bioreactors and research tools to the development of bioengineered organ implants for the esophagus, trachea, and bronchus. The company grew out of life science company Harvard Bioscience, Inc., and was spun-off in 2013.
“We decided to change our company name to Biostage to eliminate any confusion with the former parent company from which we had spun-out and to better communicate and differentiate our exciting and personalized approach to organ regeneration,” Jim McGorry, president and CEO said in a statement.
The company’s biotechnology focus can be seen in its Cellframe technology, where a biocompatible scaffolding is seeded with the recipient’s own stem cells to create implants for treatment of life-threatening conditions.
Biostage will trade under the symbol BSTG.
